Loading clinical trials...

Adjuvant Radiotherapy in High Risk Locally Advanced DTC | Clinical Trials | Clareo Health

RECRUITINGPHASE3

Adjuvant Radiotherapy in High Risk Locally Advanced DTC

The Role of Adjuvant Radiotherapy in High Risk Locally Advanced Differentiated Thyroid Cancer：a 1:1 Randomized Phase III Clinical Trial

NCT06558981•Fudan University

View on ClinicalTrials.gov

Summary

This study is a phase III randomized controlled clinical trial on the role of adjuvant radiotherapy in high-risk locally advanced differentiated thyroid cancer. Patients who meet the inclusion criteria were randomly assigned 1:1 to either the experimental group (adjuvant radiotherapy+RAI) or the control group (RAI), with LRFS as the primary endpoint of the study.

Eligibility

Age

14 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. The patient voluntarily joined this study and signed an informed consent form;
•2. Age: ≥ 14 years old,\<80 years old, male or female not limited;
•3. Histopathological diagnosis of differentiated thyroid cancer;
•4. Surgical total or near total thyroidectomy;
•5. The surgery did not achieve R0 resection, and R1/ R2 resection was performed. The volume of residual tumor in R2 resected patients is less than 2cm3;
•6. The main organ functions are normal;
•7. Good compliance and cooperation with follow-up.

Exclusion Criteria

•1. Previously received radiation therapy for the head and neck area;
•2. Differentiated thyroid cancer with poorly differentiated, or undifferentiated components;
•3. There is distant metastasis;
•4. Previously received 131I treatment;
•5. Previously received or currently receiving targeted therapy, immunotherapy, chemotherapy;
•6. Within 5 years or simultaneously suffering from other active malignant tumors. Cured local tumors, such as skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, breast carcinoma in situ, can be included in the group;
•7. Pregnant or lactating women;
•8. Other physical illnesses that affect patients' ability to receive standard treatment;
•9. According to the researchers' assessment, there may be other factors that could force the subjects to terminate the study, such as suffering from other serious illnesses (including mental illnesses) that require concurrent treatment, severe abnormal laboratory test values, family or social factors that may affect the safety of the subjects or the collection of experimental data;
•10. Individuals with claustrophobia who are unable to undergo radiation therapy;
+1 more criteria

Locations (1)

Fudan Univeristy Shanghai Cancer Center

Shanghai, China

Key Dates

Start Date

July 11, 2024

Primary Completion Date

June 1, 2031

Completion Date

June 1, 2031

Last Updated

February 27, 2026

Enrollment

124

ESTIMATED participants

Conditions

Thyroid Cancer

Interventions

Radiotherapy

RADIATION

radioiodine treatment

OTHER

Contacts

Naisi Huang, M.D.

CONTACT

86-021-64175590 huangnaisi@fudan.edu.cn

The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma

NCT06316895

Papillary Thyroid Cancer

View study

RECRUITINGPHASE2

Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

NCT07092514

Thyroid CancerCancer of the Thyroid

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 27, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Adjuvant Radiotherapy in High Risk Locally Advanced DTC

Inclusion Criteria

Exclusion Criteria

The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma

Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer

RW Study of Adjuvant Radiotherapy in Locally Advanced Thyroid Cancer

Natural History Study of Children and Adults With Medullary Thyroid Cancer

Irreversible Electroporation for Recurrent or Metastatic Cervical Lymph Node Metastases From Thyroid Cancer: A Prospective Multicenter Single-Arm Study